Anixa Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Amit Kumar
- Full Time Employees
- 5
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3150 Almaden Expressway San Jose CA United States of America 95118
- IPO Date
- Oct 7, 1983
- CIK
- 0000715446
- Website
- anixa.com
- Similar Companies
- Business
- Anixa Biosciences Inc (NASDAQ:ANIX) operates as a clinical-stage biotechnology company focused on developing therapies and vaccines for cancer treatment and prevention. The company offers a therapeutics portfolio featuring chimeric endocrine receptor T-cell (CER-T) immunotherapy, including liraltagene autoleucel (lira-cel), an FSHR-targeted CAR-T therapy exclusively licensed from The Wistar Institute for recurrent ovarian cancer, conducted in Phase 1 trials with Moffitt Cancer Center; its vaccine portfolio, developed with Cleveland Clinic, targets retired proteins in triple negative breast cancer (TNBC), ovarian cancer, and additional programs for lung, colon, and prostate cancers. Founded in 1982 and headquartered in San Jose, California, Anixa conducts operations primarily in the United States through collaborations with leading research institutions. Recent developments include World Health Organization approval in November 2025 of the international non-proprietary name liraltagene autoleucel for its CAR-T therapy, marking a milestone toward commercialization; expansion in May 2024 of its Cleveland Clinic partnership for novel cancer vaccines; a $5 million share repurchase program authorized in July 2024; and a letter of intent with VERDI Solutions for artificial intelligence applications in development.
Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
Reviewing AVAX Technologies (OTCMKTS:AVXT) & Anixa Biosciences (NASDAQ:ANIX)
Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026
Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs
Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast
Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues
Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
Water Tower Research Publishes Initiation of Coverage Report on Anixa Biosciences, Inc., “Anixa's T-Cell Innovations Show Breakthrough Potential in Solid Tumors”